Abstract:OBJECTIVE:To evaluate the role of 2-deoxy-D-glucose (2-DG) modified supermagnetic iron oxide nanoparticles (SPIO) (γ-Fe2O3@DMSA-DG NPs) in tumor detection as a magnetic resonance imaging (MRI) contrast agent.METHODS:γ-Fe2O3@DMSA-DG NPs was prepared. The degree of A549 cells targeted absorption of γ-Fe2O3@DMSA-DG NPs was detected by Prussian blue staining, colorimetric assay, T2W and multi-echo sequence MRI. γ-Fe2O3@DMSA NPs was used as a control agent, and free D-glucose as a competitive inhibitor. Human lung adenocarcinoma A549 xenograft tumor was prepared in nude mice. Sterile aqueous suspension of γ-Fe2O3@DMSA NPs or γ-Fe2O3@DMSA-DG NPs was injected into the tail vein of nude mice. Before and 6, 12, 24, 48 h after injection, MRI imaging of the mice was performed. T2 signal intensity of the tumor, brain, liver and thigh skeletal muscles, and T2 values of the tumors were measured.RESULTS:The average diameter of the particles was about 10 nm, and there were no significant differences between the diameters of γ-Fe2O3@DMSA NPs and γ- Fe2O3@DMSA-DG NPs. The IR spectra showed the C-N retractable vibration peak at γ-Fe2O3@DMSA-DG NPs surface, indicating that 2-DG was conjugated to the γ-Fe2O3@DMSA NPs. The Prussian blue staining, colorimetric assay, MRI T2 signal intensity and T2 values revealed that γ-Fe2O3@DMSA-DG NPs were significantly more absorbed by A549 cells at growth peak than γ-Fe2O3@DMSA NPs, and the absorption of γ-Fe2O3@DMSA-DG NP was inhibited by free D-glucose. The results of in vivo examination showed that before and at 6, 12, 24, 48 h after injection of γ-Fe2O3@DMSA-DG NPs, the mean T2 signal intensities of the tumors were (326.00 ± 16.26)s, (276.40 ± 5.13)s, (268.40 ± 30.58)s, (240.40 ± 25.93)s, (262.20 ± 30.04)s, respectively, and the T2 values of the tumors were (735.80 ± 20.93) ms, (645.80 ± 69.58) ms, (615.00 ± 124.61) ms, (570.60 ± 67.78) ms, and (537.80 ± 105.29) ms, respectively. However, before and at 6, 12, 24, 48 h after injection of γ-Fe2O3@DMSA NPs, the mean T2 signal intensities of the tumors were (335.60 ± 4.93)s, (290.80 ± 5.93)s, (273.40 ± 15.08)s, (327.40 ± 16.65)s, and (313.20 ± 20.45)s, respectively, and T2 values were (686.00 ± 21.44)ms, (617.80 ± 69.93)ms, (645.20 ± 85.89)ms, (669.40 ± 13.72)ms, and (608.80 ± 61.90)ms, respectively. The T2 signal intensity and T2 value of the tumors were not declined generally after injection. The liver T2 signal intensity was decreased after injection of both γ-Fe2O3@DMSA-DG NPs and γ-Fe2O3@DMSA NPs, and T2 signal intensity of the brain and muscle did not show significant changes.CONCLUSIONS:γ-Fe2O3@DMSA-DG NPs has an ability to target glucose receptors overexpressed in tumors, and may serve as a MRI contrast agent for tumor detection.

Detection of Human Breast Cancer Cells Using a 2-Deoxy-d-glucose-functionalized Superparamagnetic Iron Oxide Nanoparticles.

2-Deoxy-d-glucose Modified Supermagnetic Iron Oxide Nanoparticles Enhance the Contrasting Effect on MRI of Human Lung Adenocarcinoma A549 Tumor in Nude Mice

Breast Cancer Diagnosed by MRI Using Mesoporous TiO₂-Coated (Fe₃O₄) Nanoparticles

Mri of High-Glucose Metabolism Tumors: A Study in Cells and Mice with 2-Dg-modified Superparamagnetic Iron Oxide Nanoparticles

Ultra-Small and Metabolizable Near-Infrared Au/Gd Nanoclusters for Targeted FL/MRI Imaging and Cancer Theranostics

Construction of cRGD-iron oxide nanoparticles and its application in the tumor diagnosis by magnetic resonance imaging

Magnetic Resonance Imaging Contrast Agent: Crgd-Ferric Oxide Nanometer Particle and Its Role in the Diagnosis of Tumor

Specific Targeting of Breast Tumor by Octreotide-Conjugated Ultrasmall Superparamagnetic Iron Oxide Particles Using a Clinical 3.0-Tesla Magnetic Resonance Scanner

Nanoparticle-based MRI of metastatic human hepatocellular carcinoma: Targeting survivin gene with siRNA in an animal model

Targeting Glut1-overexpressing MDA-MB-231 cells with 2-deoxy-d-g1ucose modified SPIOs

Magnetic resonance molecular imaging of metastatic breast cancer by targeting extradomain-B fibronectin in the tumor microenvironment.

Study on angiogenesis-targeting paramagnetic nanoliposomes in MRI for diagnosis of pulmonary carcinoma

Preparation of MRI molecular probe targeting human epidermal growth factor receptor 2 and the ;preliminary study of breast cancer cell in vitro

A Dual Ligand Targeted Nanoprobe with High MRI Sensitivity for Diagnosis of Breast Cancer

Targeted Fluorescent Magnetic Nanoparticles for Imaging of Human Breast Cancer.

2-Deoxy-d-glucose Modified Magnetic Nanoparticles with Dual Functional Properties: Nanothermotherapy and Magnetic Resonance Imaging

Targeted Dual-Contrast T1- and T2-weighted Magnetic Resonance Imaging of Tumors Using Multifunctional Gadolinium-Labeled Superparamagnetic Iron Oxide Nanoparticles

Preparation of a Glucose Receptor-Mediated Tumor Targeting 2-Dg-conjugated Superparamagnetic Iron Oxide Nanoparticles and Its in Vitro Experimental Study

Co-encapsulation of Magnetic Fe3O4 Nanoparticles and Doxorubicin into Biocompatible PLGA-PEG Nanocarriers for Early Detection and Treatment of Tumours

Fe3O4-rhodamine 6G Nanoparticles: an Iron Enhanced Ph Sensitive Multimodal Probe for Fluorescence and Magnetic Resonance Imaging of Tumor Cell

Cancer Cell Detection and Imaging: MRI-SERS Bimodal Splat-Shaped Fe3O4/Au Nanocomposites